Results 1 to 10 of about 16,551 (199)
Botulinum toxin type A therapy for blepharospasm [PDF]
Cochrane Database of Systematic Reviews, 2004 Blepharospasm is a focal dystonia characterized by chronic intermittent or persistent involuntary eyelid closure due to spasmodic contractions of the orbicularis oculi muscles. Other facial and neck muscles are also frequently involved. Most cases are idiopathic and blepharospasm is generally a life-long disorder.
Cláudia C Espírito‐Santo +6 more
openaire +6 more sources
Botulinum toxin type A versus botulinum toxin type B for cervical dystonia [PDF]
Cochrane Database of Systematic Reviews, 2016 This is an update of a Cochrane review first published in 2003. Cervical dystonia is the most common form of focal dystonia and is a disabling disorder characterised by painful involuntary head posturing. There are two available formulations of botulinum toxin, with botulinum toxin type A (BtA) usually considered the first line therapy for this ...
Duarte, GS +7 more
openaire +4 more sources
Botulinum toxin type A versus botulinum toxin type B for cervical dystonia [PDF]
, 2003 Cervical dystonia is the most common form of focal dystonia. It is characterized by involuntary posturing of the head and frequently is associated with neck pain. Disability and social withdrawal are common. Most cases are idiopathic, and generally it is a life-long disorder.
J, Costa +6 more
openaire +2 more sources
Botulinum toxin type B micromechanosensor [PDF]
Proceedings of the National Academy of Sciences, 2003 Botulinum neurotoxin (BoNT) types A, B, E, and F are toxic to humans; early and rapid detection is essential for adequate medical treatment. Presently available tests for detection of BoNTs, although sensitive, require hours to days. We report a BoNT-B sensor whose properties allow detection of BoNT-B within minutes.
Edwin R. Chapman +4 more
openaire +3 more sources
Botulinum Toxin Type a in Cervical Dystonia
International Journal of Immunopathology and Pharmacology, 2012 Cervical dystonia is a syndrome characterized by anomalous postures and unintentional repetitive movements of the head and the neck. Aim of this study is to show the effectiveness of the combined treatment botulinum toxin-FKT through the use of a recent methodic of investigation, myoton, and of the classical clinical evaluations, such as Tsui and VAS ...
Marvulli R. +7 more
openaire +4 more sources
Botulinum toxin type A therapy for cervical dystonia [PDF]
Cochrane Database of Systematic Reviews, 2017 This is an update of a Cochrane Review first published in 2005. Cervical dystonia is the most common form of focal dystonia and is a highly disabling movement disorder characterised by involuntary, usually painful, head posturing. Currently, botulinum toxin type A (BtA) is considered the first line therapy for this condition.To compare the efficacy ...
Rodrigues, FB +7 more
openaire +7 more sources
Pneumothorax after botulinum toxin type A
Annals of Physical and Rehabilitation Medicine, 2012 literature. Case report.– A 27-year-old patient, with PKAN heredodegenerative dystonia, has truncal dystonia symptomatology. Suddenly, she complained of low-back pain evaluated at 10/10 on a verbal scale. Low-back pain is induced by repetitive dystonic movements with upper limbs anterior elevation, spinal and hip extension (opisthotonos).
A. Dongas +5 more
openaire +2 more sources
Mechanisms of Botulinum Toxin Type A Action on Pain [PDF]
Toxins, 2019 Already a well-established treatment for different autonomic and movement disorders, the use of botulinum toxin type A (BoNT/A) in pain conditions is now continuously expanding. Currently, the only approved use of BoNT/A in relation to pain is the treatment of chronic migraines. However, controlled clinical studies show promising results in neuropathic
Kata Bölcskei +3 more
openaire +5 more sources
The Pharmacology of Botulinum Toxin Type A
, 2022 The aim of this chapter is to structure current information clarifying the most disputable issues of botulinum neurotoxin type A (BoNT/A) pharmacology after systemic (botulism) impact and local medical application. Botulinum neurotoxin (BoNT) pharmacological features evaluated open ways to study factors affecting its biological activity: to extend ...
openaire +3 more sources
Botulinum toxin type A therapy for hemifacial spasm [PDF]
Cochrane Database of Systematic Reviews, 2004 Hemifacial spasm is characterised by unilateral involuntary contractions of muscles innervated by the facial nerve. The usual cause is a vessel touching the facial nerve near its origin from the brain stem. Although it is a benign condition it can cause significant cosmetic and functional disability.
Ana A Borges +6 more
openaire +4 more sources